PGS Sample Set (PSS): PSS000068

Sample #1

Phenotype

Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.

Sample Ancestry

European

Sample Numbers

Total number	3,157 individuals
Detailed numbers	3,157 cases (100.0%) 0 controls 100.0% Male samples
Age of Study Participants	Range : [50.0, 60.0] years
Number of Cohort(s)	1

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
UKGPCS	UK Genetic Prostate Cancer Study	—

Sample #2

Phenotype

Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.

Sample Ancestry

European

Sample Numbers

Total number	8,796 individuals
Detailed numbers	2,148 cases (24.42%) 6,648 controls 100.0% Male samples
Age of Study Participants	Range : [50.0, 69.0] years
Number of Cohort(s)	1

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
ProtecT	Prostate testing for cancer and Treatment study	—

Sample #3

Phenotype

Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.

Sample Ancestry

European

Sample Numbers

Total number	5,059 individuals
Detailed numbers	4,099 cases (81.02%) 960 controls 100.0% Male samples
Age of Study Participants	Range : [50.0, 69.0] years
Number of Cohort(s)	1

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
SEARCH	Study of Epidemiology and Risk Factors in Cancer Heredity	—